1. Home
  2. KPTI vs UNB Comparison

KPTI vs UNB Comparison

Compare KPTI & UNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPTI
  • UNB
  • Stock Information
  • Founded
  • KPTI 2008
  • UNB 1891
  • Country
  • KPTI United States
  • UNB United States
  • Employees
  • KPTI N/A
  • UNB N/A
  • Industry
  • KPTI Biotechnology: Pharmaceutical Preparations
  • UNB Major Banks
  • Sector
  • KPTI Health Care
  • UNB Finance
  • Exchange
  • KPTI Nasdaq
  • UNB Nasdaq
  • Market Cap
  • KPTI 103.5M
  • UNB 167.6M
  • IPO Year
  • KPTI 2013
  • UNB 1998
  • Fundamental
  • Price
  • KPTI $0.64
  • UNB $31.26
  • Analyst Decision
  • KPTI Strong Buy
  • UNB
  • Analyst Count
  • KPTI 4
  • UNB 0
  • Target Price
  • KPTI $5.00
  • UNB N/A
  • AVG Volume (30 Days)
  • KPTI 1.0M
  • UNB 11.3K
  • Earning Date
  • KPTI 11-05-2024
  • UNB 01-15-2025
  • Dividend Yield
  • KPTI N/A
  • UNB 4.57%
  • EPS Growth
  • KPTI N/A
  • UNB N/A
  • EPS
  • KPTI N/A
  • UNB 1.94
  • Revenue
  • KPTI $148,442,000.00
  • UNB $46,385,000.00
  • Revenue This Year
  • KPTI $6.67
  • UNB N/A
  • Revenue Next Year
  • KPTI $8.58
  • UNB N/A
  • P/E Ratio
  • KPTI N/A
  • UNB $16.24
  • Revenue Growth
  • KPTI 1.77
  • UNB N/A
  • 52 Week Low
  • KPTI $0.63
  • UNB $21.00
  • 52 Week High
  • KPTI $1.95
  • UNB $37.70
  • Technical
  • Relative Strength Index (RSI)
  • KPTI 25.28
  • UNB 49.29
  • Support Level
  • KPTI $0.75
  • UNB $31.00
  • Resistance Level
  • KPTI $0.83
  • UNB $35.98
  • Average True Range (ATR)
  • KPTI 0.05
  • UNB 1.44
  • MACD
  • KPTI -0.01
  • UNB -0.54
  • Stochastic Oscillator
  • KPTI 4.21
  • UNB 29.85

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About UNB Union Bankshares Inc.

Union Bankshares Inc operates as a community bank in the financial services industry. It offers retail and commercial banking services to its customers through its branches, ATMs, telebanking, and internet banking systems. The company provides retail banking services to individuals and commercial banking services to small and medium-sized corporations, partnerships, and sole proprietorships, as well as nonprofit organizations, local municipalities, and school districts within its market area. In addition, it also offers fiduciary and asset management services through its Asset Management Group. Geographically, all the business activity is functioned through the United States.

Share on Social Networks: